Regulation of hepatic lipid metabolism by intestine epithelium-derived exosomes

Abstract

The “gut-liver axis” is critical for the control of hepatic lipid homeostasis, where the intestine affects the liver through multiple pathways, such as nutrient uptake, gastrointestinal hormone release, and gut microbiota homeostasis. Whether intestine-originated exosomes mediate the gut’s influence on liver steatosis remains unknown. Here, we aimed to determine whether intestinal epithelium-derived exosomes (intExos) contribute to the regulation of hepatic lipid metabolism. We found that mouse intExos could be taken up by hepatic cells. Mice fed high-fat diet (HFD) received intExos showed strong resistance to liver steatosis. MicroRNA sequencing of intExos indicated the correlation between miR-21a-5p/miR-145a-5p and hepatic lipid metabolism. Both liver overexpression of miR-21a-5p and intExos containing miR-21a-5p alleviated hepatic steatosis in mice fed with HFD. Mechanistically, miR-21a-5p suppressed the expression of Ccl1 (C-C motif chemokine ligand 1) in macrophages, as well as lipid transport genes Cd36 (cluster of differentiation 36) and Fabp7 (fatty acid binding protein 7) in hepatocytes. Liver-specific inhibition of miR-145a-5p significantly reduced hepatic lipid accumulation in mice fed with HFD through negatively regulating the expression of Btg1 (BTG anti-proliferation factor 1), leading to an increase of stearoyl-CoA desaturase-1 and lipogenesis. Our study demonstrates that intExos regulate hepatic lipid metabolism and non-alcoholic fatty liver disease (NAFLD) progression via miR-21a-5p and miR-145a-5p pathways, providing novel mediators for the gut-liver crosstalk and potential targets for regulating hepatic lipid metabolism.

Keywords

exosome / non-alcoholic fatty liver disease / miR-21a-5p / miR-145a-5p / lipid metabolism

References

[1] Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis 2014;18:19–31.

[2] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol 2020;72:558–77.

[3] Wang SZ, Yu YJ, Adeli K. Role of gut microbiota in neuroendocrine regulation of carbohydrate and lipid metabolism via the microbiota-gut-brain-liver axis. Microorganisms 2020;8:527.

[4] Aron-Wisnewsky J, Vigliotti C, Witjes J et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279–97.

[5] Veziroglu EM, Mias GI. Characterizing extracellular vesicles and their diverse RNA contents. Front Genet 2020;11:700.

[6] Théry C, Witwer KW, Aikawa E et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018;7:1535750.

[7] Van Niel G, Mallegol J, Bevilacqua C et al. Intestinal epithelial exosomes carry MHC class II/peptides able to inform the immune system in mice. Gut 2003;52:1690–7.

[8] Isaac R, Reis FCG, Ying W et al. Exosomes as mediators of intercellular crosstalk in metabolism. Cell Metab 2021;33:1744–62.

[9] O’Brien K, Breyne K, Ughetto S et al. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol 2020;21:585–606.

[10] Wang W, Zhu N, Yan T et al. The crosstalk: exosomes and lipid metabolism. Cell Commun Signal 2020;18:119.

[11] Garcia NA, González-King H, Grueso E et al. Circulating exosomes deliver free fatty acids from the bloodstream to cardiac cells: possible role of CD36. PLoS One 2019;14:e0217546.

[12] Liu Y, Wang C, Wei M et al. Multifaceted roles of adipose tissue-derived exosomes in physiological and pathological conditions. Front Physiol 2021;12:669429.

[13] Chen Y, Pfeifer A. Brown fat-derived exosomes: small vesicles with big impact. Cell Metab 2017;25:759–60.

[14] Thomou T, Mori MA, Dreyfuss JM et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature 2017;542:450–5.

[15] Castaño C, Novials A, Párrizas M. Exosomes from short-term high-fat or high-sucrose fed mice induce hepatic steatosis through different pathways. Cells 2022;12:169.

[16] Deng ZB, Zhuang X, Ju S et al. Exosome-like nanoparticles from intestinal mucosal cells carry prostaglandin E2 and suppress activation of liver NKT cells. J Immunol 2013;190:3579–89.

[17] Ahn J, Lee H, Jung CH et al. Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol Nutr Food Res 2012;56:1665–74.

[18] Castillo-Armengol J, Fajas L, Lopez-Mejia IC. Inter-organ communication: a gatekeeper for metabolic health. EMBO Rep 2019;20:e47903.

[19] Huang Z, Xu A. Adipose extracellular vesicles in intercellular and inter-organ crosstalk in metabolic health and diseases. Front Immunol 2021;12:608680.

[20] Ying W, Riopel M, Bandyopadhyay G et al. Adipose tissue macrophage- derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell 2017;171:372–84.e12.

[21] Zhao J, Song Y, Zeng Y et al. Improvement of hyperlipidemia by aerobic exercise in mice through a regulatory effect of miR- 21a-5p on its target genes. Sci Rep 2021;11:11966.

[22] Sun C, Huang F, Liu X et al. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int J Mol Med 2015;35:847–53.

[23] Yamada H, Suzuki K, Ichino N et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 2013;424:99–103.

[24] Calo N, Ramadori P, Sobolewski C et al. Stress-activated miR-21/miR-21^* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. Gut 2016;65:1871–81.

[25] Wu H, Ng R, Chen X et al. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut 2016;65:1850–60.

[26] Rodrigues PM, Afonso MB, Simão AL et al. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell Death Dis 2017;8:e2748.

[27] Wang XM, Wang XY, Huang YM et al. Role and mechanisms of action of microRNA-21 as regards the regulation of the WNT/β-catenin signaling pathway in the pathogenesis of non-alcoholic fatty liver disease. Int J Mol Med 2019;44:2201–12.

[28] Loyer X, Paradis V, Hénique C et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut 2016;65:1882–94.

[29] Heymann F, Hammerich L, Storch D et al. Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology 2012;55:898–909.

[30] Shahrokhi SZ, Saeidi L, Sadatamini M et al. Can miR-145-5p be used as a marker in diabetic patients? Arch Physiol Biochem 2022;128:1175–80.

[31] He M, Wu N, Leong MC et al. miR-145 improves metabolic inflammatory disease through multiple pathways. J Mol Cell Biol 2020;12:152–62.

[32] Du J, Cheng X, Shen L et al. Methylation of miR-145a-5p promoter mediates adipocytes differentiation. Biochem Biophys Res Commun 2016;475:140–8.

[33] Schaack B, Hindré T, Quansah N et al. Microbiota-derived extracellular vesicles detected in human blood from healthy donors. Int J Mol Sci 2022;23:13787.

[34] Zhang B, Zhao J, Jiang M et al. The potential role of gut microbial- derived exosomes in metabolic-associated fatty liver disease: implications for treatment. Front Immunol 2022;13:893617.

[35] Percie du Sert N, Hurst V, Ahluwalia A et al. The ARRIVE guidelines 20: updated guidelines for reporting animal research. Br J Pharmacol 2020;177:3617–24.

[36] Li Z, Liu S, Lou J et al. LGR4 protects hepatocytes from injury in mouse. Am J Physiol Gastrointest Liver Physiol 2019;316:G123–31.

[37] Ballestri S, Nascimbeni F, Baldelli E et al. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther 2017;34:1291–326.

[38] Xia F, Ding F, Lv Y et al. A high efficient method to isolate exosomes from small intestinal epithelium. Mol Biotechnol 2019;61:325–31.

[39] Li Z, Xu G, Qin Y et al. Ghrelin promotes hepatic lipogenesis by activation of mTOR-PPARγ signaling pathway. Proc Natl Acad Sci USA 2014;111:13163–8.

RIGHTS & PERMISSIONS

2023 The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.